Christopher Viehbacher - SEC Form 4 Insider Trading Activity
Director
Summary
Updated Aug 16, 2026
Christopher Viehbacher has filed 1 SEC Form 4 filing across 1 company in the last 90 days - buying. Lifetime open-market purchases: $1.50M.
Profile
Christopher Viehbacher is President and CEO at BIOGEN INC. (BIIB). Viehbacher has reported 3 insider filings with the SEC since 2025. The most recent filing was in February 2026.
- Role
- Director
Board memberships
- BIOGEN INC.
Trading Pattern
InsiderAlpha's records for Christopher Viehbacher go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $1.50M (1 buy totaling $1.50M). The largest single buy on record is $1.50M of BRVE in 2026. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Christopher Viehbacher has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at Braveheart Bio, Inc. (BRVE) - 1 filing, 2026
- President and CEO, Director at BIOGEN INC. (BIIB) - 3 filings, 2025 to 2026
Recent Transactions
7Companies - Last 90 Days
1- Braveheart Bio, Inc. (BRVE) - 1 filing, last 2026-08-07
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Christopher Viehbacher has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Forbion Growth Opportunities Fund III Cooperatief U.A. - $64.80M of BRVE open-market activity in the last 12 months
- Erez Chimovits - $34.92M of BRVE open-market activity in the last 12 months
- ORBIMED ADVISORS LLC - $34.92M of BRVE open-market activity in the last 12 months
- AH Bio Fund IV, L.P. - $19.80M of BRVE open-market activity in the last 12 months
- Travis Murdoch - $1.50M of BRVE open-market activity in the last 12 months
- David Charles Lubner - $1000K of BRVE open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Christopher Viehbacher?
Christopher Viehbacher is President and CEO at BIOGEN INC. (BIIB). Viehbacher has reported 3 insider filings with the SEC since 2025. The most recent filing was in February 2026.…
How many SEC Form 4 filings has Christopher Viehbacher submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Christopher Viehbacher been buying or selling stock?
Recorded transactions: 1 open-market purchase ($1.50M) and 0 open-market sales across all tracked filings.
Where can I see all of Christopher Viehbacher's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Get alerts when Christopher Viehbacher files a new Form 4
Track every insider buy in real time, with AI-scored daily trade ideas and 10b5-1 plan flags.
Free during early access · No credit card required